Advertisement

Current Treatment Options in Psychiatry

, Volume 5, Issue 3, pp 313–322 | Cite as

Future Directions Incorporating Novel Medications to Reduce Repeat Overdose

  • Sade E. Johns
  • Mary Bowman
  • F. Gerard Moeller
Substance Use Disorders (FG Moeller, Section Editor)
  • 54 Downloads
Part of the following topical collections:
  1. Topical Collection on Substance Use Disorders

Abstract

Purpose of review

The use of opioids has risen dramatically in the USA and led to an increase in opioid use disorders and deaths due to opioid-related overdoses. Current treatments for opioid use disorder are not without drawbacks, so that new treatments may be helpful in reducing opioid use. This paper reviews current pharmacologic treatments for opioid use disorder as well as emerging novel treatments that may change or improve approaches to treatment.

Recent findings

The current treatments for opioid use disorder are methadone, buprenorphine, and naltrexone. Of the three, methadone has been the most studied and longest treatment used. However, because of limitations with prescribing and safety concerns with methadone, buprenorphine is becoming a widely used pharmacologic treatment alternative. Naltrexone remains less commonly utilized. New treatments such as lorcaserin and medicinal cannabis have potential to make an impact in addressing the opioid epidemic; however, controlled human studies are needed to assess their full potential.

Summary

Current treatments for opioid use disorder are beneficial, but have the disadvantage of abuse potential, compliance concerns, and prescribing limitations. Novel pharmacologic treatments may be able to address these concerns. Future research should continue to evaluate the efficacy of novel medications for the treatment of opioid use disorder.

Keywords

Opioid use disorder Opioid epidemic Medication-assisted treatment Novel treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Moeller has grant support from Indivior pharmaceuticals. Dr. Johns has nothing to disclose.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. HHS Publication No. (SMA) 17–5044. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017.Google Scholar
  2. 2.
    •• Hughes A, Williams MR, Lipari RN, Bose J, Copella EAP, Kroutil LA. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. 2016. Data on prescription drug use and misuse in the United States.Google Scholar
  3. 3.
    Rajan S, Ruggles KV, Guarino H, Mateu-Gelabert P. Heroin use and drug injection among youth also misusing prescription drugs. Substance Abuse Treat Prev Policy. 2018;42(1):144–55.Google Scholar
  4. 4.
    Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67:349–58.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Park-Lee E, Lipari RN, Hadden SL, Kroutil LA. Receipt of services for substance use and mental health issues among adults: results from the 2016 National Survey on Drug Use and Health. NSDUH Data Review. 2017.Google Scholar
  6. 6.
    Center for Disease Control and Prevention. Emergency department data show rapid increases in opioid overdose [Press release]. Retrieved from https://www.cdc.gov/media/releases/2018/p0306-vs-opioids-overdoses.html.
  7. 7.
  8. 8.
    •• Sharma A, Kelly SM, Mitchel SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorder. Curr Psychiatry Rep. 2017;19(6):35. Current barriers to substance abuse treatment medications.CrossRefPubMedGoogle Scholar
  9. 9.
    • Ling W. A perspective on opioid pharmacotherapy: where we are and how we got here. J Neuroimmune Pharmacol. 2016;11(3):394–00. History of substance abuse and current trends.CrossRefPubMedGoogle Scholar
  10. 10.
    • Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. MT Sinai J Med. 2000;67(5–6):347–64. Methadone treatment history and current trends.PubMedGoogle Scholar
  11. 11.
    Itzoe M, Guarnieri M. New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther. 2017;11:1429–37.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    • Sunilkumar MM, Lockman K. Practical pharmacology of methadone: a long-acting opioid. Indian J Palliat Care. 2018;24(Suppl 1):S10–4. Pharmacology and current use of methadone in substance abuse.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Leahy LG. The opioid epidemic: what does it mean for nurses? J Psychosoc Nurs Ment Health Serv. 2017;55(1):18–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend 2016;160:112–8.Google Scholar
  15. 15.
    Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63(3):200–5.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Rosenthal RN, Goradia W. Advances in the delivery of buprenorphine for opioid dependence. Drug Des Devel Ther. 2017;11:2493–505.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015. 2015;313(16):1636–44.Google Scholar
  18. 18.
    Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ. Cost-effectiveness of injectable extended-release naltrexone compared to methadone maintenance and buprenorphine maintenance treatment for opioid dependence. Subst Abus. 2015;36(2):226–31.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    •Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Wood GE, et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018;27(3):177–87.Addresses practices for managing persons with moderate to severe opioid use disorder.Google Scholar
  20. 20.
    Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. 2017;74(12):1197–1205.Google Scholar
  21. 21.
    Bond AJ, Witton J. Perspectives on the pharmacological treatment of heroin addiction. Clin Med Insights: Psychiatr. 2017;8:1–10.Google Scholar
  22. 22.
    Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M. Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial. Nicotine Tob Res 2016;19(8):944–51.Google Scholar
  23. 23.
    Gannon BM, Sulima A, Rice KC, Collins GT. Inhibition of cocaine and 3,4-methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats. J Pharmacol Exp Ther. 2018;364(2):359–66.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lipari RN, Williams M, Van Horn SL. Why do adults misuse prescription drugs? The CBHSQ Report. Rockville MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental health Services, 2017.Google Scholar
  25. 25.
    •• Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, et al. Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem Neurosci. 2017;8(5):1065–73. Evidence of lorcaserin reducing oxycodone self-administrationCrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    •• Wu X, Pang G, Zhang YM, Li G, Xu S, Don L, et al. Activation of serotonin in 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice. Neurosci Lett. 2015;607:23–8. Evidence of lorcaserin suppressing behavior sensitization and withdrawal.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    • Baron EPComprehensive review of medical marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long trip it’s been. Headache 2015;55(6):885–916. A review of medicinal marijuana and headache.Google Scholar
  28. 28.
    • Owens B. Drug development: the treasure chest. Nature. 2015;525(7570):S6–8. A good read on the pharmacology of medicinal marijuana.CrossRefPubMedGoogle Scholar
  29. 29.
    Gupta S. Why I changed my mind on weed. 2013. https://www.cnn.com/2013/08/08/health/gupta-changed-mind-marijuana/. Accessed 23 May 2018.
  30. 30.
    Gupta S. Dr. Sanjay Gupta to Jeff Sessions: medicinal marijuana could save many addicted to opioids. 2018. https://www.cnn.com/2018/04/24/health/medical-marijuana-opioid-epidemic-sanjay-gupta/. Accessed 23 May 2018.
  31. 31.
    •• Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PLoS One. 2017;12(11):e0187795. Evidence of medicinal cannabis reducing prescription opioid use.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    •• Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29–42. Evidence of medical cannabis laws reducing addiction and overdose-related deaths.CrossRefPubMedGoogle Scholar
  33. 33.
    Shapiro GK, Buckley-Hunter L. What every adolescent needs to know: cannabis can cause psychosis. J Psychosom Res. 2010;69(6):533–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Del Buno MG, O’Quinn MP, Garcia P, Gerszten E, Roberts C, Moeller FG, et al. Cardiac arrest due to ventricular fibrillation in a 23-year-old woman with broken heart syndrome. Cardiovasc Pathol. 2017;30:78–81.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Drug and Alcohol StudiesVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations